Like my fellow sparring partner, Ryan Fuhrmann, I also consider myself to be a contrarian investor. So I can definitely respect those who've taken a somewhat contrarian approach by buying the down-and-out shares of Pfizer (NYSE:PFE) or Johnson & Johnson (NYSE:JNJ). However, little or nothing I've heard has convinced me that either of these stocks would be a good investment now.

Ryan makes a good point: Johnson & Johnson is well-diversified, and thus better-protected against downturns (in the stent market, for instance) than a smaller, less-diversified name like Boston Scientific (NYSE:BSX). That said, J&J's massive size and diverse operations make the needle that much tougher to move. Strong results in any one of J&J's business lines would have little effect on its stock.

Don't get me wrong: J&J is a good company. I just happened to peg it as a future underperformer.

Check out the other arguments in this duel, and then vote for a winner.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.